Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock Rating Lowered by Zacks Research

Pelthos Therapeutics (NYSEAMERICAN:PTHS) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Wednesday, Zacks reports.

Separately, Oppenheimer dropped their price target on Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a research report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $55.40.

Pelthos Therapeutics Stock Down 2.3%

PTHS opened at $20.50 on Wednesday. The company has a market cap of $78.52 million, a PE ratio of -0.94 and a beta of 3.07. Pelthos Therapeutics has a twelve month low of $18.19 and a twelve month high of $37.50. The company has a 50-day moving average price of $24.40 and a 200 day moving average price of $25.18. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%.The firm had revenue of $15.60 million for the quarter. Sell-side analysts expect that Pelthos Therapeutics will post -15.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pelthos Therapeutics

An institutional investor recently raised its stake in Pelthos Therapeutics stock. Knott David M Jr lifted its stake in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 9.3% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 21,073 shares of the company’s stock after acquiring an additional 1,792 shares during the period. Knott David M Jr owned 0.63% of Pelthos Therapeutics worth $443,000 as of its most recent filing with the Securities & Exchange Commission. 77.96% of the stock is currently owned by hedge funds and other institutional investors.

Pelthos Therapeutics Company Profile

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited.